| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 25 Feb 2026 | 17 Feb 2026 |
| Sanofi Consumer Healthcare India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/02/2026 inter alia to consider and approve the Audited Financial Statements for the Quarter and Financial Year ended 31st December 2025 Sanofi Consumer Healthcare India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/02/2026 ,inter alia, to consider and approve Intimation of Board Meeting to consider recommendation of dividend, if any, for the financial year ended December 31, 2025 (As Per BSE Announcement Dated on:20.02.2026) The Board of Directors at its meeting held today considered and approved the Audited Financial Statements of the Company for the quarter and financial year ended 31st December 2025 (As Per BSE Announcement Dated on:25.02.2026) | ||
| Board Meeting | 12 Nov 2025 | 5 Nov 2025 |
| Sanofi Consumer Healthcare India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2025 inter alia to consider and approve Unaudited Financial Results for the quarter and nine months ended 30th September 2025 We wish to inform you that the Board of Directors at its meeting held today i.e., Wednesday, 12th November 2025, inter-alia considered and approved the Unaudited Financial Results for the quarter and nine months ended 30th September 2025. (As Per BSE Announcement Dated on: 12/11/2025) | ||
| Board Meeting | 4 Aug 2025 | 29 Jul 2025 |
| Sanofi Consumer Healthcare India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/08/2025 inter alia to consider and approve Unaudited Financial Results for the quarter and half year ended 30th June 2025 We refer to our letter dated 29th July 2025 informing you of our Board Meeting that was scheduled today. In this regard, we wish to inform you that the Board of Directors at its meeting held today i.e. Monday, 4th August 2025, inter alia considered and approved the Unaudited Financial Results for the quarter and half year ended 30th June 2025. Outcome of Board Meeting for consideration and approval of Unaudited Financial Results for the quarter and half year ended 30th June 2025 (As Per BSE Announcement Dated on :04.08.2025) | ||
| Board Meeting | 2 May 2025 | 25 Apr 2025 |
| Sanofi Consumer Healthcare India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/05/2025 inter alia to consider and approve the Unaudited Financial Results for the Quarter ended 31st March 2025 We refer to our letter dated 25th April 2025 informing you of our Board Meeting that was scheduled today. In this regard, we wish to inform you that the Board of Directors at its meeting held today i.e., Friday, 2nd May 2025, inter-alia considered and approved the Unaudited Financial Results for the quarter ended 31st March 2025 As Per BSE Announcement Dated on 02.05.2025 | ||
The company faced headwinds in the December 2024 quarter (Q4) as it reported a significant decline in earnings.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
